GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Ghrelin regulates the endoplasmic reticulum stress signalling pathway in gestational diabetes mellitus.
Li. Xinying X; Ji. Qun Q; Zhong. Chunrong C; Wu. Congyin C; Wu. Jinchan J; Yuan. Caihong C; Ran. Jianmin J
Key Findings
- Acyl ghrelin treatment improved metabolic markers (glucose, cholesterol, triglycerides, insulin) in gestational diabetes mice.
- Ghrelin reduced endoplasmic reticulum stress proteins (PERK, ATF6, IRE1α, GRP78, CHOP, caspase‑12) and beta‑cell apoptosis; the effect was reversed by the GHRP‑6 antagonist.
- In cultured pancreatic cells, ghrelin protected against high‑glucose or tunicamycin‑induced stress and apoptosis, boosting insulin output.
Practical Outcomes
- The study hints that enhancing ghrelin signaling might help control blood sugar and cellular stress, but the data are limited to pregnant mouse models. Using GHRP‑6 as an antagonist would negate these effects. More human research is needed before recommending ghrelin‑based or GHRP‑6 protocols for metabolic health.
Summary
In pregnant mice with diabetes, giving the hormone ghrelin lowered blood sugar, cholesterol, triglycerides and insulin levels, protected the pancreas, and reduced cell stress and death. Blocking ghrelin with a GHRP-6 variant cancelled these benefits, showing ghrelin’s role in easing cellular stress.
Abstract
We aimed to investigate the effects and mechanisms of the ghrelin-regulated endoplasmic reticulum stress (ERS) signalling pathway in gestational diabetes mellitus (GDM). Pregnant female C57BL/6 mice were randomly divided into a normal group, GDM group (high-fat diet + STZ), GDM + ghrelin group (acyl ghrelin), and GDM + ghrelin + ghrelin inhibitor group ([D-lys3]-GHRP-6). We measured body weight, the intake of water and food, glucose, cholesterol, triglyceride and fasting insulin levels in each group. HE staining was used to observe the morphological changes in the pancreas. The TUNEL method was used to detect the apoptosis rate of islet cells. qPCR and Western boltting were performed to detect the relative expression levels of PERK, ATF6, IREIα, GRP78, CHOP and caspase-12, which are related to the ERS signalling pathway in the pancreas. Then, NIT-1 cells were cultured to verify whether ghrelin regulates ERS under high-glucose or tunicamycin conditions. Compared with the GDM group, the GDM + ghrelin group showed improved physical conditions and significantly decreased the fasting blood glucose, glucose tolerance, cholesterol, triglyceride and fasting insulin levels. Damaged islet areas were inhibited by ghrelin in the GDM group. The GDM + ghrelin group showed reduced β-cell apoptosis compared to the GDM and GDM + ghrelin + ghrelin inhibitor groups. ERS-associated factors (PERK, ATF6, IREIα, GRP78, CHOP and caspase-12) mRNA and protein levels were obviously lower in the GDM + ghrelin group than in the GDM group, while expression levels were restored in the inhibitor group. Ghrelin treatment improved the high-glucose or tunicamycin-induced apoptosis, increased insulin levels and upregulation of GRP78, CHOP and caspase-12 in NIT-1 cells. Ghrelin suppressed ERS signalling and apoptosis in GDM mice and in NIT-1 cells. This study established a link between ghrelin and GDM, and the targeting of ERS with ghrelin represents a promising therapeutic strategy for GDM.
Study Information
pubmed
2024
2024-03-28T00:00:00.000Z
10.1016/j.bbrc.2024.149844
2
43